Shanghai Nianxing Industrial Co., Ltd
China
Product Name: Tolvaptan-d7
Price:
Purity: 99.0%
Stocking Period: 10 Day
Contact: Yang

1246818-18-7

1246818-18-7 structure

Name: Tolvaptan-d7
Chemical Name: Tolvaptan-d7
CAS Number: 1246818-18-7
Molecular Formula: C₂₆H₁₈D₇ClN₂O₃
Molecular Weight: 455.984
Catalog: Signaling Pathways Autophagy Autophagy
Create Date: 2021-06-07 20:13:38
Modify Date: 2024-01-16 08:39:19
Tolvaptan-D7 (OPC-41061-D7) is the deuterium labeled Tolvaptan. Tolvaptan is a selective, competitive arginine vasopressin receptor 2 antagonist with an IC50 of 1.28μM for the inhibition of AVP-induced platelet aggregation[1][2].

Name	Tolvaptan-d7
Synonyms	Tolvaptan-d7 N-{4-[(7-Chloro-5-hydroxy-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]-3-methylphenyl}-2-(2H3)methyl(2H4)benzamide Benzamide-2,3,4,5-d4, N-[4-[(7-chloro-2,3,4,5-tetrahydro-5-hydroxy-1H-1-benzazepin-1-yl)carbonyl]-3-methylphenyl]-6-(methyl-d3)-

Description	Tolvaptan-D7 (OPC-41061-D7) is the deuterium labeled Tolvaptan. Tolvaptan is a selective, competitive arginine vasopressin receptor 2 antagonist with an IC50 of 1.28μM for the inhibition of AVP-induced platelet aggregation[1][2].
Related Catalog	Research Areas >> Cancer Research Areas >> Cardiovascular Disease Research Areas >> Endocrinology Signaling Pathways >> GPCR/G Protein >> Vasopressin Receptor Signaling Pathways >> Autophagy >> Autophagy
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
References	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. Friedman B, Cirulli J.Hyponatremia in critical care patients: Frequency, outcome, characteristics, and treatment with the vasopressin V(2)-receptor antagonist tolvaptan.J Crit Care. 2012 Aug 8. [3]. Inomata T.Tolvaptan (vasopressin receptor antagonist).Nihon Rinsho. 2011 Nov;69 Suppl 9:408-11. [4]. Vaduganathan M, Gheorghiade M, Pang PS, Konstam MA, Zannad F, Swedberg K, Grinfeld L, Burnett JC Jr, Krasa HB, Zimmer C, Blair J, Ouyang J, Maggioni AP; EVEREST investigators.Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment.J Cardiovasc Med (Hagerstown). 2012 Jul;13(7):415-22. [5]. Y Yamamura et al. OPC-41061, a Highly Potent Human Vasopressin V2-Receptor Antagonist: Pharmacological Profile and Aquaretic Effect by Single and Multiple Oral Dosing in Rats. J. Pharmacol. Exp. Ther. 1998, 287(3), 860-867. [6]. RW Schrier et al. Tolvaptan, a Selective Oral Vasopressin V2-Receptor Antagonist, for Hyponatremia. N Engl J Med 2006, 355, 2099-2112.

Density	1.3±0.1 g/cm3
Boiling Point	594.4±50.0 °C at 760 mmHg
Molecular Formula	C₂₆H₁₈D₇ClN₂O₃
Molecular Weight	455.984
Flash Point	313.3±30.1 °C
Exact Mass	455.199310
LogP	4.09
Vapour Pressure	0.0±1.8 mmHg at 25°C
Index of Refraction	1.664

1246818-18-7	1296212-29-7
150683-30-0	1330180-51-2
1133208-42-0	2747918-94-9
1175992-76-3	73509-20-3
1218911-70-6	1584701-10-9
1158522-08-7	940364-43-2
134104-43-1	131615-57-1
1243443-72-2	6906-52-1
1797277-25-8	930439-75-1
1018584-77-4	1375289-11-4